Research graph
References from Ethambutol Population Pharmacokinetics and Pharmacodynamics From a Phase 3 Confirmatory Trial for the Treatment of Tuberculosis. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial
10.1016/j.cct.2020.105938 · 2020 · External reference
Four-month rifapentine regimens with or without moxifloxacin for Tuberculosis
10.1056/nejmoa2033400 · 2021 · External reference
The Mycobacterium tuberculosis cell wall: an alluring drug target for developing newer anti-TB drugs-A perspective
10.1111/cbdd.14612 · 2024 · External reference
Unresolved reference
External reference
The ocular toxicity of ethambutol and its relation to dose
10.1111/j.1749-6632.1966.tb45532.x · 1966 · External reference
Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids
10.1128/aac.43.3.568 · 1999 · External reference
Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods
10.1038/psp.2013.14 · 2013 · External reference
Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance
10.1038/psp.2013.26 · 2013 · External reference
Population pharmacokinetics of ethambutol in South African tuberculosis patients
10.1128/aac.00274-11 · 2011 · External reference
Pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in newly diagnosed pulmonary TB patients in Tanzania
10.1371/journal.pone.0141002 · 2015 · External reference
Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study
10.1093/jac/dku478 · 2015 · External reference
Pharmacokinetics of ethambutol in children and adults with tuberculosis
2004 · External reference
Population pharmacokinetics and pharmacogenetics of ethambutol in adult patients coinfected with Tuberculosis and HIV
10.1128/aac.01583-19 · 2020 · External reference
Kinetics of oral ethambutol in the normal subject
10.1002/cpt1977225part1615 · 1977 · External reference
Disposition kinetics of ethambutol in man
10.1007/bf01059382 · 1980 · External reference
Recommendation of pharmacokinetics/pharmacodynamics target of ethambutol to suppress tuberculosis resistance: a population pharmacokinetics study on a large prospective cohort
10.1016/j.ijantimicag.2023.106840 · 2023 · External reference
Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people
10.1128/aac.05623-11 · 2012 · External reference
Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients
10.1128/aac.50.4.1170-1177.2006 · 2006 · External reference
Evaluation of the adequacy of WHO revised dosages of the first-line antituberculosis drugs in children with Tuberculosis using population pharmacokinetic modeling and simulations
10.1128/aac.00008-18 · 2018 · External reference
Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs
10.1007/bf03261926 · 2012 · External reference
Update on diabetic nephropathy: core curriculum 2018
10.1053/j.ajkd.2017.10.026 · 2018 · External reference
Treatment of Tuberculosis
10.1056/nejmra1413919 · 2015 · External reference
